References
- Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 Mar 23; 342((12))836–43
- Ridker P. M. High‐sensitivity C‐reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 Apr 3; 103((13))1813–8
- Wang T. J., Larson M. G., Levy D., Benjamin E. J., Leip E. P., Omland T. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. N Engl J Med 2004 Feb 12; 350((7))655–63
- Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., Hildebrandt P. N‐terminal pro‐brain natriuretic peptide, C‐reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005 Apr 6; 293((13))1609–16
- Gustafsson F., Badskjær J., Steensgaard hansen F., Poulsen A., Hildebrandt P. Value of N‐terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2003; 3: 141–6
- Mcdonagh T. A., Cunningham A. D., Morrison C. E., Mcmurray J. J., Ford I., Morton J. J. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001 Jul; 86((1))21–6
- Redfield M. M., Rodeheffer R. J., Jacobsen S. J., Mahoney D. W., Bailey K. R., Burnett J. C, Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community‐based study. Circulation 2004 Jun 29; 109((25))3176–81
- Nielsen O. W., Mcdonagh T. A., Robb S. D., Dargie H. J. Retrospective analysis of the cost‐effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003 Jan 1; 41((1))113–20
- Heidenreich P. A., Gubens M. A., Fonarow G. C., Konstam M. A., Stevenson L. W., Shekelle P. G. Cost‐effectiveness of screening with B‐type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004 Mar 17; 43((6))1019–26
- Hildebrandt P., Boesen M., Olsen M., Wachtell K., Groenning B. N‐terminal pro brain natriuretic peptide in arterial hypertension–a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004 Mar 15; 6((3))313–7
- Vasan R. S., Benjamin E. J., Larson M. G., Leip E. P., Wang T. J., Wilson P. W. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002 Sep 11; 288((10))1252–9
- Olsen M. H., Wachtell K., Tuxen C., Fossum E., Bang L. E., Hall C. N‐terminal pro‐brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004 Aug; 22((8))1597–604
- Bibbins‐domingo K., Ansari M., Schiller N. B., Massie B., Whooley M. A. Is B‐type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med 2004 Apr 15; 116((8))509–16
- Omland T., Aakvaag A., Vik‐mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996 Sep; 76((3))232–7
- Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in stable coronary heart disease. N Engl J Med 2005 Feb 17; 352((7))666–75